Cell>Point announced today that it has received a letter from the US Food & Drug Administration saying that they have agreed with the company's proposed Special Protocol Assessment (SPA) for Cell>Point's Phase III pivotal clinical study of technetium-99m-EC-G in lung cancer.
According to the SPA, this Phase III trial will assess the use of Cell>Point's molecular imaging product candidate, technetium-99m-EC-G (EthylenediCysteine-n-acetyl-Glucosamine) in the diagnosis and staging of lung cancer.
In the study, patients will receive technetium-99m-EC-G intravenously, and an image will be captured by a Single Photon Emission Computed Tomography (SPECT) camera (aka a gamma camera).
Source: Therapeutics Daily